GlassScriptPhysician profile
David F Jaffe
NPI 1427023811
$2,512.44
in general payments reported to CMS, 2019-2025
24 companies · $534 in 2025
The $534 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $95.76 · 2021: $199 · 2022: $180 · 2023: $669 · 2024: $637 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,640.76 |
| Education | $198.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $399.41 | 2019-2025 | |
| Janssen Biotech, INC. | $378.50 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $221.31 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $201.69 | 2022-2025 | Blu-U, Odomzo |
| Abbvie INC. | $198.11 | 2019-2024 | |
| Ucb, INC. | $162.19 | 2021-2025 | Bimzelx, Cimzia |
| Organon LLC | $120.53 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $110.61 | 2023-2024 | Dupixent |
| Amgen INC. | $108.76 | 2022-2025 | Otezla |
| Pfizer INC. | $77.92 | 2021-2023 | |
| Incyte Corporation | $70.95 | 2021-2025 | Opzelura |
| Genzyme Corporation | $63.75 | 2019-2021 | |
| Galderma Laboratories, L.P. | $62.40 | 2021-2025 | Aklief, Nemluvio |
| Dermavant Sciences, INC. | $52.46 | 2023 | Vtama |
| Sandoz INC. | $44.92 | 2023-2025 | Hyrimoz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $42.52 | 2025 | Ameluz |
| Vyne Pharmaceuticals INC. | $35.96 | 2020 | |
| Lilly USA, LLC | $33.45 | 2019-2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $25.66 | 2025 | Adbry |
| Almirall LLC | $24.86 | 2023 | Klisyri |
| Sanofi-Aventis U.S. LLC | $24.40 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.41 | 2022 | |
| Genentech USA, INC. | $14.36 | 2019 | |
| Journey Medical Corporation | $14.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.